Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program.

Details

Ressource 1Download: 29344270_BIB_13DAD73D00CC.pdf (399.79 [Ko])
State: Public
Version: Final published version
License: CC BY-NC 4.0
Serval ID
serval:BIB_13DAD73D00CC
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program.
Journal
Journal of Cancer
Author(s)
Balmelli C., Railic N., Siano M., Feuerlein K., Cathomas R., Cristina V., Güthner C., Zimmermann S., Weidner S., Pless M., Stenner F., Rothschild S.I.
ISSN
1837-9664 (Print)
ISSN-L
1837-9664
Publication state
Published
Issued date
2018
Peer-reviewed
Oui
Volume
9
Number
2
Pages
250-255
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
javax.xml.bind.JAXBElement@5a6991ed
Differentiated thyroid cancer (DTC) accounts for approximately 95% of thyroid carcinomas. In the metastatic RAI-refractory disease, chemotherapy has very limited efficacy and is associated with substantial toxicity. With increasing knowledge of the molecular pathogenesis of DTC, novel targeted therapies have been developed. Lenvatinib is a tyrosine kinase inhibitor (TKI) with promising clinical activity based on the randomized phase III SELECT trial. In Switzerland, a Named Patient Program (NPP) was installed to bridge the time gap to Swissmedic approval. Here, we report the results from the Swiss Lenvatinib NPP including patients with metastatic RAI-refractory DTC. javax.xml.bind.JAXBElement@7407c55a Main inclusion criteria for the Swiss NPP were RAI-refractory DTC, documented disease progression, Eastern Cooperative Oncology Group (ECOG) performance status 0-3. The number of previous therapies was not limited. The Swiss Lenvatinib NPP was initiated in June 2014 and was closed in October 2015 with the approval of the drug. javax.xml.bind.JAXBElement@1c5cb2cc Between June 2014 and October 2015, 13 patients with a median age of 72 years have been enrolled. Most patients (69%) had at least one prior systemic therapy, mainly sorafenib. 31% of patients showed a PR and 31% SD. Median progression free survival was 7.2 months and the median overall survival was 22.7 months. Dose reduction due to adverse events was necessary in 7 patients (53%). At the time of analysis 6 patients (47%) were still on treatment with a median time on treatment of 9.98 months. javax.xml.bind.JAXBElement@713fc2d4 Our results show that lenvatinib has reasonable clinical activity in unselected patients with RAI-refractory thyroid cancer with nearly two-third of patients showing clinical benefit. The toxicity profile of lenvatinib is manageable.

Keywords
differentiated thyroid cancer, lenvatinib, radioiodine refractory, sorafenib., tyrosine kinase inhibitors
Pubmed
Web of science
Open Access
Yes
Create date
27/01/2018 14:25
Last modification date
20/08/2019 13:42
Usage data